Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

BACKGROUND: Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD1...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Hanren, Wu, Zhiqiang, Jia, Hejin, Tong, Chuan, Guo, Yelei, Ti, Dongdong, Han, Xiao, Liu, Yang, Zhang, Wenying, Wang, Chunmeng, Zhang, Yajing, Chen, Meixia, Yang, Qingming, Wang, Yao, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126394/
https://www.ncbi.nlm.nih.gov/pubmed/32245502
http://dx.doi.org/10.1186/s13045-020-00856-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126394/
https://www.ncbi.nlm.nih.gov/pubmed/32245502
http://dx.doi.org/10.1186/s13045-020-00856-8

Ejemplares similares